Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization

Vaccine

Volumn 18, Issue 26, 2000, Pages 3031-3039

  Kollaritsch, H ^a   Cryz Jr, S J ^b   Lang, A B ^b   Herzog, C ^b   Que, J U ^b   Wiedermann, G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Berna Biotech AG   (Switzerland)

Author keywords

S. typhi Ty21a; V. cholerae CVD103 HgR; Vaccine

Indexed keywords

BACTERIUM ANTIBODY; CHOLERA VACCINE; LIVE VACCINE; TOXIN ANTIBODY; TYPHOID VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SEROCONVERSION; VIBRIO CHOLERAE;

EID: 0034237169     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00101-8     Document Type: Article

References (28)

1. Davis R., Spencer C.M. Live oral cholera vaccine. A preliminary review of its pharmacology and clinical potential in providing protective immunity against cholera. Clin. Immunother. 4:1995;235-247.
2. Levine M.M., Tacket C.O., Galen J.E., et al. Progress in development of new attenuated strains of Salmonella typhi as live oral vaccines against typhoid fever. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New generation vaccines. 2nd ed. 1997;437-446 Marcel Dekker, New York.
3. Offit P.A., Clark H.F., Kapikian A.Z. Vaccines against rotavirus. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New generation vaccines. 2nd ed. 1997;659-671 Marcel Dekker, New York.
4. Robbins F.C. Polio - historical. Plotkin S.A., Mortimer E.A. Vaccines. 1994;137-154 Saunders, Philadelphia, PA.
5. Cryz S.J. Jr, Levine M.M., Losonsky G., Kaper J.B., Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD103-HgR live oral cholera vaccine in Swiss adults. Infect. Immun. 60:1992;3916-3917.
6. Forrest B.D., LaBrooy J.T., Dearlove C.E., Shearman D.J.C. Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a. Infect. Immun. 60:1992;465-471.
7. Kantele A., Mäkelä P.H. Different profiles of the human immune response to primary and secondary immunization with an oral Salmonella typhi Ty21a vaccine. Vaccine. 9:1991;423-428.
8. Kollaritsch H., Fürer E., Herzog C., Wiedermann G., Que J.U., Cryz S.J. Jr. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD103-HgR live oral vaccines. Infect. Immun. 64:1996;1454-1457.
9. Kollaritsch H., Que J.U., Kunz C., Wiedermann G., Herzog C., Cryz S.J. Jr. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J. Infect. Dis. 175:1997;871-875.
10. Cryz S.J. Jr, Que J.U., Levine M.M., Wiedermann G., Kollaritsch H. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-Cholera (Vibrio cholerae CVD103-HgR) vaccine in healthy adults. Infect. Immun. 63:1995;1336-1339.
11. Levine M.M., Ferreccio C., Cryz S.J. Jr, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 336:1990;891-894.
12. Levine M.M., Taylor D.N., Ferreccio C. Typhoid vaccines come of age. Pediat. Infect. Dis. J. 8:1989;374-381.
13. Cryz S.J. Jr, Vanprapar N., Thisyakorn U., Olanratmanee T., Losonsky G., Levine M.M., et al. Safety and immunogenicity of Salmonella typhi Ty21a Vaccine in young Thai children. Infect. Immun. 61:1993;1149-1151.
14. Wasserman S.S., Losonsky G.A., Noriega F., Tacket C.O., Castañeda E., Levine M.M. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine. 12:1994;1000-1003.
15. Tacket C.O., Losonsky G., Nataro J.P., et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD103-HgR. J. Infect. Dis. 166:1992;837-841.
16. Kantele A., Kantele J.M., Arvilommi H., Mäkelä P.H. Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine. 9:1991;428-431.
17. Losonsky G.A., Tacket C.O., Wasserman S.S., Kaper J.B., Levine M.M. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect. Immun. 61:1993;729-733.
18. Clements J.D., Van Loon F., Sack D.A., et al. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J. Infect. Dis. 163:1991;1235-1242.
19. Glass R.I., Svennerholm A.-M., Khan M.R., Huda S., Huq M.I., Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151:1985;236-246.
20. Levine M.M., Ferreccio C., Black R.E., Tacket C.O., Germanier R. The Chilean Typhoid Committee. Progress in vaccines against typhoid fever. Rev. Infect. Dis. 11:(Suppl. 3):1989;S552-S567.
21. Reisinger E.C., Grasmug E., Krejs G.J. Antibody response after vaccination against typhoid fever in Kurdish refugee camp. Lancet. 343:1994;918-919.
22. Gotuzzo E., Butron B., Seas C., et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61:1993;3994-3997.
23. Su-Arehawaratana P., Singharaj P., Taylor D.N., et al. Safety and immunogenicity of different immunization regimens of CVD103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165:1992;1042-1048.
24. Cancellieri V., Fara G.M. Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine. J. Infect. Dis. 151:1985;482-484.
25. D'Amelio R., Tagliabue A., Nencioni L., et al. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect. Immun. 56:1988;2731-2735.
26. Kantele A., Häkkinen M., Moldoveanu Z., Lu A., Savilahti E., Alvarez R.D., et al. Differences in immune responses induced by oral and rectal immunizaitons with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect. Immun. 66:1998;5630-5635.
27. Levine M.M., Kaper J.B., Herrington D., et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD103-HgR. Lancet. 2:1988;467-470.
28. Viret J.-F., Favre D., Wegmüller B., Herzog C., Que J.U., Cryz S.J., et al. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and non-invasive live attenuated bacteria. Infect. Immun. 67:1999;3680-3685.